Argent Biopharma Ltd (RGT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Argent Biopharma Ltd (RGT) has a cash flow conversion efficiency ratio of 0.379x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-3.27 Million ≈ $-2.31 Million USD) by net assets (AU$-8.63 Million ≈ $-6.11 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Argent Biopharma Ltd (RGT) defensive interval to measure how many days the company can operate on defensive assets alone.
Argent Biopharma Ltd - Cash Flow Conversion Efficiency Trend (2006–2023)
This chart illustrates how Argent Biopharma Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Argent Biopharma Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Argent Biopharma Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CHINA HEALTH GRP HD-10
F:VNL1
|
N/A |
|
Nordon Indústrias Metalúrgicas S/A
SA:NORD3
|
0.017x |
|
S&U plc
LSE:SUS
|
-0.193x |
|
Flow Beverage Corp
TO:FLOW
|
0.038x |
|
Presidio Property Trust
NASDAQ:SQFT
|
-0.038x |
|
TAURUS ENERGY AB B SK120
F:8LU
|
-0.007x |
|
Erayak Power Solution Group Inc. Class A Ordinary Shares
NASDAQ:RAYA
|
-0.068x |
|
WesCan Energy Corp
V:WCE
|
0.254x |
Annual Cash Flow Conversion Efficiency for Argent Biopharma Ltd (2006–2023)
The table below shows the annual cash flow conversion efficiency of Argent Biopharma Ltd from 2006 to 2023. For the full company profile with market capitalisation and key ratios, see Argent Biopharma Ltd market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-06-30 | AU$-8.03 Million ≈ $-5.68 Million |
AU$-11.99 Million ≈ $-8.48 Million |
1.492x | +163.57% |
| 2022-06-30 | AU$5.18 Million ≈ $3.67 Million |
AU$-12.16 Million ≈ $-8.60 Million |
-2.347x | -170.67% |
| 2021-06-30 | AU$13.83 Million ≈ $9.78 Million |
AU$-11.99 Million ≈ $-8.48 Million |
-0.867x | +73.05% |
| 2020-06-30 | AU$3.09 Million ≈ $2.19 Million |
AU$-9.96 Million ≈ $-7.05 Million |
-3.218x | -446.82% |
| 2019-06-30 | AU$10.80 Million ≈ $7.64 Million |
AU$-6.35 Million ≈ $-4.50 Million |
-0.588x | -26.86% |
| 2018-06-30 | AU$12.69 Million ≈ $8.98 Million |
AU$-5.89 Million ≈ $-4.17 Million |
-0.464x | -57.30% |
| 2017-06-30 | AU$15.79 Million ≈ $11.17 Million |
AU$-4.66 Million ≈ $-3.29 Million |
-0.295x | -7.40% |
| 2016-06-30 | AU$11.73 Million ≈ $8.30 Million |
AU$-3.22 Million ≈ $-2.28 Million |
-0.275x | +14.35% |
| 2015-06-30 | AU$1.93 Million ≈ $1.36 Million |
AU$-617.71K ≈ $-437.07K |
-0.321x | -208.50% |
| 2014-06-30 | AU$4.55 Million ≈ $3.22 Million |
AU$-472.74K ≈ $-334.49K |
-0.104x | -54.01% |
| 2013-06-30 | AU$7.94 Million ≈ $5.62 Million |
AU$-536.08K ≈ $-379.31K |
-0.067x | +86.00% |
| 2012-06-30 | AU$787.42K ≈ $557.15K |
AU$-379.45K ≈ $-268.48K |
-0.482x | -17.80% |
| 2011-06-30 | AU$828.30K ≈ $586.08K |
AU$-338.82K ≈ $-239.74K |
-0.409x | -223.14% |
| 2010-06-30 | AU$-3.14 Million ≈ $-2.22 Million |
AU$-1.04 Million ≈ $-737.66K |
0.332x | -99.30% |
| 2009-06-30 | AU$-8.79K ≈ $-6.22K |
AU$-416.04K ≈ $-294.38K |
47.331x | +20017.04% |
| 2008-06-30 | AU$1.94 Million ≈ $1.37 Million |
AU$-460.26K ≈ $-325.67K |
-0.238x | +44.28% |
| 2007-06-30 | AU$3.81 Million ≈ $2.70 Million |
AU$-1.63 Million ≈ $-1.15 Million |
-0.426x | -2973.25% |
| 2006-06-30 | AU$2.76 Million ≈ $1.95 Million |
AU$41.00K ≈ $29.01K |
0.015x | -- |
About Argent Biopharma Ltd
Argent BioPharma Limited, a clinical-stage biopharmaceutical company, develops nano-engineered therapeutics that reset the balance between the nervous and immune systems in Malta, Slovenia, Australia, and internationally. The company's principal product candidates include CimetrA, which is in phase III clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I c… Read more